M
Marilyn Pike
Researcher at Novartis
Publications - 8
Citations - 1483
Marilyn Pike is an academic researcher from Novartis. The author has contributed to research in topics: Placebo & Osteoarthritis. The author has an hindex of 7, co-authored 8 publications receiving 1443 citations. Previous affiliations of Marilyn Pike include Chiron Corporation.
Papers
More filters
Journal ArticleDOI
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2 Double-Blind, Randomized, Controlled Clinical Trial
Michael Simons,Brian H. Annex,Roger J. Laham,Neal S. Kleiman,Timothy D. Henry,Harold L. Dauerman,James E. Udelson,Ernesto V. Gervino,Marilyn Pike,M. J. Whitehouse,Thomas Moon,Nicolas A. Chronos +11 more
TL;DR: A single intracoronary infusion of rFGF2 does not improve exercise tolerance or myocardial perfusion but does show trends toward symptomatic improvement at 90 (but not 180) days.
Journal ArticleDOI
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure
Raimund Hirschberg,Joel D. Kopple,Pamela A. Lipsett,Ernest Benjamin,Joseph P. Minei,Timothy E Albertson,Mark A. Munger,Michael Metzler,Gary P. Zaloga,Michael J. Murray,Stephen F. Lowry,John D. Conger,Wade McKeown,Michael H. O'Shea,Robert P. Baughman,Kenneth E. Wood,Marilyn Haupt,Roger Kaiser,Hank Simms,David G. Warnock,Warren R. Summer,Raymond L. Hintz,Brian Myers,Kathrine Haenftling,William Capra,Marilyn Pike,Hans Peter Guler +26 more
TL;DR: rhIGF-I does not accelerate the recovery of renal function in ARF patients with substantial comorbidity and is not safe in patients with ARF.
Journal ArticleDOI
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study.
Roger J. Laham,Nicholas A Chronos,Marilyn Pike,Mark E Leimbach,James E. Udelson,Justin D. Pearlman,Roderic I. Pettigrew,M. J. Whitehouse,Carl Yoshizawa,Michael Simons +9 more
TL;DR: Intracoronary administration of rFGF-2 appears safe and is well tolerated over a 100-fold dose range (0.33 to 0.36 microk/kg) and preliminary evidence of efficacy is tempered by the open-label uncontrolled design of the study.
Journal ArticleDOI
Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease
James E. Udelson,Vasken Dilsizian,Roger J. Laham,Nicolas A. Chronos,John Vansant,Michel Blais,James R. Galt,Marilyn Pike,Carl Yoshizawa,Michael Simons +9 more
TL;DR: The preliminary data suggest that the administration of rFGF-2 to patients with advanced coronary disease resulted in an attenuation of stress-induced ischemia and an improvement in resting myocardial perfusion; these findings are consistent with a favorable effect of therapeutic angiogenesis.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease.
Mark A. Bush,Emil Samara,M. J. Whitehouse,Carl Yoshizawa,Deborah Novicki,Marilyn Pike,Roger J. Laham,Michael Simons,Nicolas A. Chronos +8 more
TL;DR: While a clear PK/PD dose‐response relationship was not established, a trend toward hypotension and tachycardia with higher rFGF‐2 doses was observed, indicating linear pharmacokinetics over the dose range examined.